Cargando…
Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment
BACKGROUND & AIMS: Individuals at risk of (H1N1) influenza A infection are recommended to receive vaccination. Chronic hepatitis C (CHC) patients receiving treatment might be at a higher risk of respiratory bacterial infections after influenza infection. However, there are no observational studi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493585/ https://www.ncbi.nlm.nih.gov/pubmed/23144908 http://dx.doi.org/10.1371/journal.pone.0048610 |
_version_ | 1782249291631296512 |
---|---|
author | Hernández-Guerra, Manuel González-Méndez, Yanira de Molina, Patricia Gimeno-García, Antonio Z. Carrillo, Marta Casanova, Carlos Pumarola, Tomás Jimenez, Alejandro Hernández-Porto, Miriam Torres, Álvaro Quintero, Enrique |
author_facet | Hernández-Guerra, Manuel González-Méndez, Yanira de Molina, Patricia Gimeno-García, Antonio Z. Carrillo, Marta Casanova, Carlos Pumarola, Tomás Jimenez, Alejandro Hernández-Porto, Miriam Torres, Álvaro Quintero, Enrique |
author_sort | Hernández-Guerra, Manuel |
collection | PubMed |
description | BACKGROUND & AIMS: Individuals at risk of (H1N1) influenza A infection are recommended to receive vaccination. Chronic hepatitis C (CHC) patients receiving treatment might be at a higher risk of respiratory bacterial infections after influenza infection. However, there are no observational studies evaluating the immunogenicity, tolerance and acceptance of 2009 influenza A vaccine in CHC patients. METHODS: We evaluated the immunogenicity of influenza A vaccine (Pandemrix®) by using the hemagglutination inhibition (HI) titers method in a well defined cohort of CHC patients receiving or not receiving pegylated-interferon and ribavirin, and compared it with healthy subjects (controls). A group of patients with inflammatory bowel disease (IBD) under immunosuppression, thought to have a lower immune response to seasonal influenza vaccine, were also included as a negative control group. In addition, tolerance to injection site reactions and acceptance was assessed by a validated questionnaire (Vaccinees' perception of injection-VAPI-questionnaire). RESULTS: Of 114 subjects invited to participate, 68% accepted and, after exclusions, 72 were included. Post-vaccination geometric mean titers and seroprotection/seroconversion rates were optimal in CHC patients with ongoing treatment (n = 15; 232, CI95% 46–1166; 93%; 93%), without treatment (n = 10; 226, CI95% 69–743: 100%; 100%) and controls (n = 15;168, CI95% 42–680; 93%; 86%) with no differences between groups (P = 0.8). In contrast, IBD patients had a significantly lower immunogenic response (n = 27; 60, CI95% 42–680;66%;66%; P = 0.006). All the groups showed a satisfactory tolerance although CHC patients with ongoing treatment showed more local discomfort after vaccine injection. CONCLUSION: There appeared to be no differences between CHC patients and healthy controls in serological response and acceptance of (H1N1) influenza vaccination. |
format | Online Article Text |
id | pubmed-3493585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34935852012-11-09 Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment Hernández-Guerra, Manuel González-Méndez, Yanira de Molina, Patricia Gimeno-García, Antonio Z. Carrillo, Marta Casanova, Carlos Pumarola, Tomás Jimenez, Alejandro Hernández-Porto, Miriam Torres, Álvaro Quintero, Enrique PLoS One Research Article BACKGROUND & AIMS: Individuals at risk of (H1N1) influenza A infection are recommended to receive vaccination. Chronic hepatitis C (CHC) patients receiving treatment might be at a higher risk of respiratory bacterial infections after influenza infection. However, there are no observational studies evaluating the immunogenicity, tolerance and acceptance of 2009 influenza A vaccine in CHC patients. METHODS: We evaluated the immunogenicity of influenza A vaccine (Pandemrix®) by using the hemagglutination inhibition (HI) titers method in a well defined cohort of CHC patients receiving or not receiving pegylated-interferon and ribavirin, and compared it with healthy subjects (controls). A group of patients with inflammatory bowel disease (IBD) under immunosuppression, thought to have a lower immune response to seasonal influenza vaccine, were also included as a negative control group. In addition, tolerance to injection site reactions and acceptance was assessed by a validated questionnaire (Vaccinees' perception of injection-VAPI-questionnaire). RESULTS: Of 114 subjects invited to participate, 68% accepted and, after exclusions, 72 were included. Post-vaccination geometric mean titers and seroprotection/seroconversion rates were optimal in CHC patients with ongoing treatment (n = 15; 232, CI95% 46–1166; 93%; 93%), without treatment (n = 10; 226, CI95% 69–743: 100%; 100%) and controls (n = 15;168, CI95% 42–680; 93%; 86%) with no differences between groups (P = 0.8). In contrast, IBD patients had a significantly lower immunogenic response (n = 27; 60, CI95% 42–680;66%;66%; P = 0.006). All the groups showed a satisfactory tolerance although CHC patients with ongoing treatment showed more local discomfort after vaccine injection. CONCLUSION: There appeared to be no differences between CHC patients and healthy controls in serological response and acceptance of (H1N1) influenza vaccination. Public Library of Science 2012-11-08 /pmc/articles/PMC3493585/ /pubmed/23144908 http://dx.doi.org/10.1371/journal.pone.0048610 Text en © 2012 Hernández-Guerra et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Hernández-Guerra, Manuel González-Méndez, Yanira de Molina, Patricia Gimeno-García, Antonio Z. Carrillo, Marta Casanova, Carlos Pumarola, Tomás Jimenez, Alejandro Hernández-Porto, Miriam Torres, Álvaro Quintero, Enrique Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment |
title | Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment |
title_full | Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment |
title_fullStr | Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment |
title_full_unstemmed | Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment |
title_short | Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment |
title_sort | immunogenicity and acceptance of influenza a (h1n1) vaccine in a cohort of chronic hepatitis c patients receiving pegylated-interferon treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493585/ https://www.ncbi.nlm.nih.gov/pubmed/23144908 http://dx.doi.org/10.1371/journal.pone.0048610 |
work_keys_str_mv | AT hernandezguerramanuel immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT gonzalezmendezyanira immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT demolinapatricia immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT gimenogarciaantonioz immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT carrillomarta immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT casanovacarlos immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT pumarolatomas immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT jimenezalejandro immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT hernandezportomiriam immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT torresalvaro immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment AT quinteroenrique immunogenicityandacceptanceofinfluenzaah1n1vaccineinacohortofchronichepatitiscpatientsreceivingpegylatedinterferontreatment |